Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Larkin

Showing results (181-190 of 418) with videos related to

Pageof 42
Sort By:
European Journal of Cancer (Oxford, England : 1990)|May 25, 2023
Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroidsSimona Manacorda, Maria De Toro Carmena, Ciara Malone, et al.
European Urology Open Science|March 4, 2022
Patient-reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 CountriesRachel Giles, Deborah Maskens, Robert Bick, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 30, 2025
Impact of the Type of Dialysate Acid Concentrate Container on the Environmental Footprint of Hemodialysis CentersRodrigo Martínez Cadenas, Julia Audije-Gil, María Dolores Arenas, et al.
Plos Medicine|November 20, 2024
Economic, cultural, and social inequalities in potentially inappropriate medication: A nationwide survey- and register-based study in DenmarkAmanda Paust, Claus Vestergaard, Susan M Smith, et al.
European Radiology|September 28, 2022
Optimisation of b-values for the accurate estimation of the apparent diffusion coefficient (ADC) in whole-body diffusion-weighted MRI in patients with metastatic melanomaAnnemarie K Knill, Matthew D Blackledge, Andra Curcean, et al.
Anticancer Research|July 2, 2014
A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experienceCharlotte Benson, Joanna Vitfell-Rasmussen, Marco Maruzzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 4, 2011
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanomaJohn M Kirkwood, Lars Bastholt, Caroline Robert, et al.
BMC Nephrology|May 21, 2026
Greener dialysis in practice: life cycle assessment of sustainable practice changes in haemodialysis careAbass Fehintola, Maaike K Van Gelder, A A F Crooijmans, et al.
Current Oncology Reports|September 24, 2024
Risk Stratification, Screening and Treatment of BRAF/MEK Inhibitors-Associated CardiotoxicityIsabelle Senechal, Maria Sol Andres, Jieli Tong, et al.
Pigment Cell & Melanoma Research|June 11, 2014
The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysisSimon J Furney, Samra Turajlic, Gordon Stamp, et al.
Pageof 42

Showing results (181-190 of 418) with videos related to

Sort By:
Pageof 42
European Journal of Cancer (Oxford, England : 1990)|May 25, 2023
Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroidsSimona Manacorda, Maria De Toro Carmena, Ciara Malone, et al.
European Urology Open Science|March 4, 2022
Patient-reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 CountriesRachel Giles, Deborah Maskens, Robert Bick, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 30, 2025
Impact of the Type of Dialysate Acid Concentrate Container on the Environmental Footprint of Hemodialysis CentersRodrigo Martínez Cadenas, Julia Audije-Gil, María Dolores Arenas, et al.
Plos Medicine|November 20, 2024
Economic, cultural, and social inequalities in potentially inappropriate medication: A nationwide survey- and register-based study in DenmarkAmanda Paust, Claus Vestergaard, Susan M Smith, et al.
European Radiology|September 28, 2022
Optimisation of b-values for the accurate estimation of the apparent diffusion coefficient (ADC) in whole-body diffusion-weighted MRI in patients with metastatic melanomaAnnemarie K Knill, Matthew D Blackledge, Andra Curcean, et al.
Anticancer Research|July 2, 2014
A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experienceCharlotte Benson, Joanna Vitfell-Rasmussen, Marco Maruzzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 4, 2011
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanomaJohn M Kirkwood, Lars Bastholt, Caroline Robert, et al.
BMC Nephrology|May 21, 2026
Greener dialysis in practice: life cycle assessment of sustainable practice changes in haemodialysis careAbass Fehintola, Maaike K Van Gelder, A A F Crooijmans, et al.
Current Oncology Reports|September 24, 2024
Risk Stratification, Screening and Treatment of BRAF/MEK Inhibitors-Associated CardiotoxicityIsabelle Senechal, Maria Sol Andres, Jieli Tong, et al.
Pigment Cell & Melanoma Research|June 11, 2014
The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysisSimon J Furney, Samra Turajlic, Gordon Stamp, et al.
Pageof 42